The listing below shows our latest News Items and is updated regularly. If you wish to post a news item please select the 'Post News' button on the right. The displayed news feed starts on 1st August 2016. Older items can be found here.
Arecor and its partner, non-profit company, Global Alliance for Livestock Veterinary Medicines (GALVmed), have successfully stabilised liquid formulations of vaccines to combat two major diseases of livestock across the developing world including Africa, Asia and the Middle East
In this work, the ArestatTM technology has been applied to enable a vaccine to be distributed pre-prepared in a liquid format without the requirement for in-field reconstitution from the freeze-dried powder form
ArestatTM technology has also been applied to reduce the cost of a batch of vaccine diluent by 96 per cent., thereby improving its distribution and uptake by farmers
Arecor’s formulation technology work has been supported by Innovate UK through UK aid of the UK government and the Bill & Melinda Gates Foundation
Cambridge, UK., 8th December 2017: Arecor Ltd (“the Company”), a leader in developing superior biopharmaceuticals through the application of an innovative formulation technology ...
Read the rest of entry »
Oxford MESTar, in collaboration with the Cell and Gene Therapy Catapult and AK Biomedical, has won a grant from Innovate UK to support the development of a novel manufacturing system intended to dramatically reduce the cost of production of CAR-T therapies.
Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection, will announce its financial results for the third quarter and nine months ended 31 October 2017 on 6 December 2017.
About Summit Therapeutics
Summit is a biopharmaceutical company focused on the discovery, development and commercialisation of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programs focused on the genetic disease, Duchenne muscular dystrophy, and the infectious disease, Clostridium difficile infection. Further information is available at www.summitplc.com and Summit can be followed on Twitter (@summitplc).
For more information, please contact:
Glyn Edwards / Richard Pye (UK office)
44 (0)1235 443 951
Activate Science, an annual event series organised by Thermo Fisher Scientific and attended by laboratory personnel across Europe, reached delegates at 28 customer sites in 2017.
HSC-BANKER® from AMSBIO is a new optimised GMP grade cryopreservation medium for the banking of hematopoietic stem cellsisolated from umbilical cord blood, peripheral blood and bone marrow.
The BioHub Birmingham®, which provides flexible laboratory space for pre-revenue life science companies, has announced its expansion to meet the growing demand for laboratory space in the Midlands.
NASA to evaluate the use of Isansys’ physiological monitoring tools to learn how to monitor explorers as they travel into space. A NASA exploration scientist set off on his mission to Antarctica being monitored by the Patient Status Engine, a physiological data collection platform which provides monitoring of individuals wirelessly and in real-time.
MSD, known as Merck and Co., Inc., in the US and Canada, has today announced its commitment to establish a state of the art life sciences discovery research facility in London, focussed on early bioscience discovery and entrepreneurial innovation
German-headquartered Qiagen are one of the firms expected to expand into a campus in the city
OBN aims to provide sector NEWS that is relevant to our Membership. We filter information from a variety of sources, publish items ourselves and will publish items of News from our Members. Press releases about OBN can be found here.
This is an impromptu noticeboard to let people know about events, other things that are happening, perhaps lab equipment for sale etc. Just drop an email to us, email@example.com, and we will post.